Startups
Rznomics
Rznomics is a South Korean biotechnology company developing RNA rewriting therapeutics using trans-splicing ribozymes. Its platform recognizes disease-associated RNA and replaces targeted RNA sequences with therapeutic RNA, supporting treatments for cancer and genetic or degenerative diseases. Its RZ-001 program targets hTERT-associated cancer biology in liver cancer and glioblastoma; the pipeline also includes Alzheimer’s disease and inherited retinal degeneration programs. The company develops a self-circularizing RNA platform for additional therapeutic applications.
Founded 2017